Q4 2026 Supriya Lifescience Ltd Earnings Call Transcript
Key Points
- Supriya Lifescience Ltd (BOM:543434) achieved a significant regulatory milestone with the USFDA inspection resulting in only one minor observation, highlighting their strong compliance culture.
- The company reported its highest ever revenue and EBITDA performance for the year, with Q4 FY26 revenues reaching INR277 crores, a 50% year-on-year growth.
- Export segment remains a key growth driver, contributing 82% of the annual revenues, with Europe showing healthy growth.
- New product launches in cardiovascular and ADHD segments have shown strong demand, contributing to revenue growth.
- The company has secured all necessary clearances for the Patalganga land, paving the way for future capacity expansion and growth.
- Geopolitical challenges, including supply chain disruptions and elevated crude prices, impacted Q4 FY26 revenue by INR10 crores.
- Despite the strong performance, the company faces industry-wide headwinds such as intermittent shortages and elevated solvent prices.
- The growth trajectory towards the INR1,000 crore revenue milestone by FY27 may not be linear due to scheduled maintenance shutdowns.
- The US market remains a small contributor to revenues, with only 1% of sales in Q4 FY26, despite having USFDA approval.
- The company is experiencing increased working capital days, rising to 170 days in FY26 from 158 days in FY25, impacting cash flow conversion.
Ladies and gentlemen, good day, and welcome to the Supriya Lifescience Limited Q4 FY26 earnings conference call. (Operator Instructions)
Please note that this conference is being recorded. I will now hand the conference over to Ms. Sneha Salian from EY IR for opening remarks. Thank you, and over to you.
Thank you, Ryan. A warm welcome to all the participants to the Supriya Lifescience Limited Q4 FY26 earnings conference call. The investor presentation and the financial results are available on the company website and on the stock exchanges.
Please note anything said on this call, which reflects our outlook for the future or which can be construed as a forward-looking statement must be viewed in conjunction with the risks that the company faces. This conference call is being recorded and the transcript along with the audio of the same, will be made available on the website of the company as well as on the exchanges.
Please also note that the audio of the conference call is the copyright
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
